TITLE

Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe

AUTHOR(S)
Vercauteren, Jurgen; Wensing, Annemarie M. J.; van de Vijver, David A. M. C.; Albert, Jan; Balotta, Claudia; Hamouda, Osamah; Kücherer, Claudia; Struck, Daniel; Schmit, Jean-Claude; Åsjö, Birgitta; Bruckova, Marie; Camacho, Ricardo J.; Clotet, Bonaventura; Coughlan, Suzie; Grossman, Zehava; Horban, Andrzej; Korn, Klaus; Kostrikis, Leondios; Nielsen, Claus; Paraskevis, Dimitrios
PUB. DATE
November 2009
SOURCE
Journal of Infectious Diseases;11/15/2009, Vol. 200 Issue 10, p1503
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The SPREAD Programme investigated prospectively the time trend from September 2002 through December 2005 of transmitted drug resistance (TDR) among 2793 patients in 20 European countries and in Israel with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection. The overall prevalence of TDR was 8.4% (225 of 2687 patients; 95% confidence interval [CI], 7.4%-9.5%), the prevalence of nucleoside reverse-transcriptase inhibitor (NRTI) resistance was 4.7% (125 of 2687 patients; 95% CI, 3.9%-5.5%), the prevalence of nonucleoside reverse-transcriptase inhibitor (NNRTI) resistance was 2.3% (62 of 2687 patients; 95% CI, 1.8%-2.9%), and the prevalence of protease inhibitor (PI) resistance was 2.9% (79 of 2687 patients; 95% CI, 2.4%- 3.6%). There was no time trend in the overall TDR or in NRTI resistance, but there was a statistically significant decrease in PI resistance (Pp.04) and in NNRTI resistance after an initial increase (Pp.02). We found that TDR appears to be stabilizing in Europe, consistent with recent reports of decreasing drug resistance and improved viral suppression in patients treated for HIV-1 infection.
ACCESSION #
45082411

 

Related Articles

  • Cost Effectiveness of Darunavir/Ritonavir in Highly Treatment-Experienced, HIV-1-Infected Adults in the USA. Mauskopf, Josephine; Brogan, Anita; Martin, Silas; Smets, Erik // PharmacoEconomics;2010 Supplement, Vol. 28, p83 

    Introduction: Darunavir is a new protease inhibitor (PI) that is co-administered with low-dose ritonavir and has demonstrated substantial efficacy in clinical trials of highly treatment-experienced patients when combined with an optimized background regimen (with or without enfuvirtide). This...

  • Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study. Ying Cao; Yang Han; Jing Xie; Qu Cui; Lixia Zhang; Yijia Li; Yanling Li; Xiaojing Song; Ting Zhu; Taisheng Li // BMC Infectious Diseases;2013, Vol. 13 Issue 1, p1 

    Background: The aim of this study was to investigate the impact of a tenofovir disoproxil fumarate (TDF) plus ritonavir-boosted protease inhibitor (PI/r) regimen on renal function in Chinese HIV-infected patients. Methods: Seventy-five HIV-1 infected patients failing first-line antiretroviral...

  • Antiretrovirals in Pregnancy: A Note of Caution. Watts, D. Heather; Mofenson, Lynne M. // Journal of Infectious Diseases;Dec2012, Vol. 206 Issue 11, p1639 

    The author discusses maternal-to-child transmission (MTCT) of human immunodeficiency virus (HIV). He is critical of the antenatal highly active antiretroviral therapy (HAART) for all women regardless of maternal CD4+ cell count. He reflects to the guidelines issued by the World Health...

  • CD4[sup+] T Cell Count Recovery in HIV Type 1-Infected Patients Is Independent of Class of Antiretroviral Therapy. Khanna, Nina; Opravil, Milos; Furrer, Hansjakob; Cavassini, Matthias; Vernazza, Pietro; Bernasconi, Enos; Weber, Rainer; Hirschel, Bernard; Battegay, Manuel; Kaufmann, Gilbert R. // Clinical Infectious Diseases;10/15/2008, Vol. 47 Issue 8, p1093 

    Background. In recent years, treatment options for human immunodeficiency virus type 1 (HIV-1) infection have changed from nonboosted protease inhibitors (PIs) to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) and boosted PI-based antiretroviral drug regimens, but the impact on...

  • HIV: implication in Burkitt lymphoma. Tsfasman, T. M.; Klibi, M.; Pichugin, A. M.; Lipinski, M.; Vassetzky, Y. S. // Biopolymers & Cell;2012, Vol. 28 Issue 4, p285 

    The risk of Burkitt lymphoma (BL) is increased in HIV-infected patients as compared to general population in Europe and in the US. This effect might be due to immune suppression and low CD4-cell counts associated with the development of AIDS. However, there is also evidence of a direct effect of...

  • Predicting AIDS-related events using CD4 percentage or CD4 absolute counts. Pirzada, Yasmin; Khuder, Sadik; Donabedian, Haig // AIDS Research & Therapy;2006, Vol. 3, p20 

    Background: The extent of immunosuppression and the probability of developing an AIDS-related complication in HIV-infected people is usually measured by the absolute number of CD4 positive T-cells. The percentage of CD4 positive cells is a more easily measured and less variable number. We...

  • Prevalence of intestinal parasitic infections in HIV-infected individuals and their relationship with immune status. Gupta, K.; Bala, M.; Deb, M.; Muralidhar, S.; Sharma, D. K. // Indian Journal of Medical Microbiology;Apr2013, Vol. 31 Issue 2, p161 

    Background and Objectives: Intestinal parasitic infection is a common entity in patients infected with human immunodeficiency virus (HIV). These infections may lead to fatal complications in the immuno suppressed individuals. The aim of the present study was to determine the prevalence of...

  • Yellow Fever Vaccination of Human Immunodeficiency Virus--Infected Patients: Report of 2 Cases. Receveur, M.C.; Thiebaut, R.; Vedy, S.; Malvy, D.; Mercie, P.; Le Bras, M. // Clinical Infectious Diseases;9/1/2000, Vol. 31 Issue 3, pE7 

    Presents a brief report on the use of yellow fever vaccination in HIV-infected patients without severe immunosuppression. Immune function in vaccination efficacy; Importance of the CD4 cell counts on response to vaccination.

  • Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children. Larru, Beatriz; de Mendoza, Carmen; Bellón, José Ma; de José, Ma Isabel; Mellado, Ma José; Soriano, Vincent; Muñoz-Fernandez, Ma Angeles; Ramos, José T. // BMC Infectious Diseases;2007, Vol. 7 Issue 1, p55 

    Background: The impact of HIV drug resistance mutations in salvage therapy has been widely investigated in adults. By contrast, data available of predictive value of resistance mutations in pediatric population is scarce. Methods: A multicenter, retrospective, observational study was conducted...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics